- S1 ]* S+ D- U. P9 v: @: A7 U
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:& T* b; M; g6 U, @5 s
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. # t6 A) q& t7 Q" Qhttp://www.ncbi.nlm.nih.gov/pubmed/229681840 E9 q! o& a4 b' F Q3 }/ b